<?xml version="1.0" encoding="UTF-8"?>
<ref id="B21-pharmaceuticals-12-00060">
 <label>21.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Sebastián</surname>
    <given-names>U.U.</given-names>
   </name>
   <name>
    <surname>Ricardo</surname>
    <given-names>A.V.A.</given-names>
   </name>
   <name>
    <surname>Alvarez</surname>
    <given-names>B.C.</given-names>
   </name>
   <name>
    <surname>Cubides</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Luna</surname>
    <given-names>A.F.</given-names>
   </name>
   <name>
    <surname>Arroyo-Parejo</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Acuña</surname>
    <given-names>C.E.</given-names>
   </name>
   <name>
    <surname>Quintero</surname>
    <given-names>A.V.</given-names>
   </name>
   <name>
    <surname>Villareal</surname>
    <given-names>O.C.</given-names>
   </name>
   <name>
    <surname>Pinillos</surname>
    <given-names>O.S.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Zika virus-induced neurological critical illness in Latin America: Severe Guillain-Barre Syndrome and encephalitis</article-title>
  <source>J. Crit. Care</source>
  <year>2017</year>
  <volume>42</volume>
  <fpage>275</fpage>
  <lpage>281</lpage>
  <pub-id pub-id-type="doi">10.1016/j.jcrc.2017.07.038</pub-id>
  <pub-id pub-id-type="pmid">28806562</pub-id>
 </element-citation>
</ref>
